New Funds Could Shorten Waiting Lists For AIDS Drugs | WAMU 88.5 - American University Radio
Filed Under:

New Funds Could Shorten Waiting Lists For AIDS Drugs

Play associated audio

The Obama administration last week announced nearly $80 million in grants to increase access to AIDS care across the United States. But will the money be enough to eliminate waiting lists for the AIDS Drug Assistance Program?

Advocates aren't sure. The program, known as ADAP, provides a safety net for people with HIV who have no means of paying for the drugs they need to fight the virus.

For the past few years, ADAP demand has outpaced funding. Nationwide, 1,800 people are now on a waiting list, with Georgia and Virginia accounting for more than half of those cases. The latest national data are here.

Murray Penner, of the National Alliance of State and Territorial AIDS Directors, says it's hard to tell if the new funding will be enough to handle states' waitlists. He thinks they will disappear, but only for a year or two.

"It's very difficult to predict these things, because there are so many variables that go into the serving of individuals that need medications," Penner said.

James Lark is one of the people affected. Now 47 years old, Lark was 30 when he learned that he was HIV-positive. He has gone in and out of phases when he takes care of his condition.

"I've been positive now for over 17 years, but when I first found out I just went with it," Lark says. "My brother had passed away with AIDS. I was dead within, and just kept living my life and wasn't taking my life seriously."

Three years ago, Lark was homeless when he decided it was time to get a handle on his health. He qualified for Georgia's AIDS Drug Assistance Program, which paid for his HIV drugs — nearly $20,000 a year.

Lark is now on government assistance and doesn't have to depend on ADAP. But he says his Social Security benefits will end in September.

"That means I'll have to go back on ADAP. And I'll be on the waiting list," he says.

Funding, drug costs and the number of people seeking treatment are constantly changing. All of those variables affect how many people are on the waiting list.

For example, Georgia recently adopted a policy of treatment upon diagnosis. Research indicates that means a longer, better life for many with HIV. But it also adds to the cost of care in a state that can't meet current demand.

The pharmacy at Atlanta's Ponce De Leon Center provides drugs and other services for more than 5,200 HIV/AIDS patients. But with the potential for hundreds of new patients, the center's Jacque Muther isn't sure how they'll accommodate them.

"It's going to be a big challenge," Muther says. "I don't know how they're going to meet it. This new money is not going to resolve that."

This story is part of a collaboration with NPR, WABE and Kaiser Health News.

Copyright 2012 National Public Radio. To see more, visit http://www.npr.org/.

NPR

Why Afghanistan's 'Underground Girls' Skirt Tradition To Live As Boys

In a new book, journalist Jenny Nordberg writes about the bacha posh, young girls who dress up like boys to enjoy the freedoms of being an Afghan male for as long as they can.
NPR

Keeping Heirloom Apples Alive Is 'Like A Chain Letter' Over Many Centuries

Scott Farm in Vermont grows 100 apple varieties, some of them dating back to the 1700s. These apples may not look as pretty as the Red Delicious, but what they lack in looks they make up for in taste.
WAMU 88.5

New Anthony Brown Video Accuses Opponent Of 'Hiding' And 'Lying"

Democrat Anthony Brown unveiled a new web video today alleging that Republican Larry Hogan is "hiding" his positions on contentious issues like abortion and gun control.
NPR

Tech Week: Smartphone Privacy, Cyberstalking, Alibaba's Big Debut

Chinese e-commerce giant Alibaba makes the biggest debut on the NYSE ever. The details, and the other tech stories that piqued our interest, are in this week's roundup.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.